Conservative management of low-risk utuc

Fatima Z. Husain, Mesut Remzi, Vitaly Margulis, Sima P. Porten, Surena F. Matin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Conservative management of upper tract urothelial cancer (UTUC) treats tumor, prevents disease progression, lowers potential morbidity, and avoids unnecessary loss of renal function by avoiding nephroureterectomy. Limitations associated with conservative therapies include the potential for undetected disease progression. Patients with UTUC are more difficult to stage clinically than in bladder cancer. Endoscopic management can be performed ureteroscopically or percutaneously. Ideal indications include a unifocal tumor, small tumor size, and low-grade disease. A positive selective cytology suggests the presence of higher grade disease and potentially more advanced pathological T stage. Endoscopic technique is critical both for accurate diagnostic purposes and for safe performance of the procedure. The results of endoscopic therapy are highly dependent on tumor factors, with lowgrade tumors having much better results than high-grade tumors. The use of adjuvant topical therapy after complete endoscopic tumor control remains unclear. The strongest role for topical therapy for UTUC is for CIS, when it is used as primary therapy. The use of segmental or distal ureterectomy and partial nephrectomy for UTUC has narrow indications with the latter needing to be applied extremely selectively. Nephroureterectomy remains the gold standard treatment, but comes at the cost of significant loss of renal function. Single-dose treatment of the bladder after nephroureterectomy is considered a new standard of care, and could be considered an option by extension of this logic, to single-dose treatment after endoscopic therapy of the upper tracts.

Original languageEnglish (US)
Title of host publicationUpper Tract Urothelial Carcinoma
PublisherSpringer New York
Pages119-130
Number of pages12
ISBN (Print)9781493915019, 9781493915002
DOIs
StatePublished - Jan 1 2015

Fingerprint

Neoplasms
Therapeutics
Disease Progression
Conservative Treatment
Kidney
Standard of Care
Nephrectomy
Urinary Bladder Neoplasms
Cell Biology
Urinary Bladder
Morbidity

Keywords

  • Renal pelvis cancer
  • Surgical treatments
  • Survival
  • Ureteral cancer
  • Urothelial cancer

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Husain, F. Z., Remzi, M., Margulis, V., Porten, S. P., & Matin, S. F. (2015). Conservative management of low-risk utuc. In Upper Tract Urothelial Carcinoma (pp. 119-130). Springer New York. https://doi.org/10.1007/978-1-4939-1501-9_5

Conservative management of low-risk utuc. / Husain, Fatima Z.; Remzi, Mesut; Margulis, Vitaly; Porten, Sima P.; Matin, Surena F.

Upper Tract Urothelial Carcinoma. Springer New York, 2015. p. 119-130.

Research output: Chapter in Book/Report/Conference proceedingChapter

Husain, FZ, Remzi, M, Margulis, V, Porten, SP & Matin, SF 2015, Conservative management of low-risk utuc. in Upper Tract Urothelial Carcinoma. Springer New York, pp. 119-130. https://doi.org/10.1007/978-1-4939-1501-9_5
Husain FZ, Remzi M, Margulis V, Porten SP, Matin SF. Conservative management of low-risk utuc. In Upper Tract Urothelial Carcinoma. Springer New York. 2015. p. 119-130 https://doi.org/10.1007/978-1-4939-1501-9_5
Husain, Fatima Z. ; Remzi, Mesut ; Margulis, Vitaly ; Porten, Sima P. ; Matin, Surena F. / Conservative management of low-risk utuc. Upper Tract Urothelial Carcinoma. Springer New York, 2015. pp. 119-130
@inbook{400c73efdf564d36b674194d37708c84,
title = "Conservative management of low-risk utuc",
abstract = "Conservative management of upper tract urothelial cancer (UTUC) treats tumor, prevents disease progression, lowers potential morbidity, and avoids unnecessary loss of renal function by avoiding nephroureterectomy. Limitations associated with conservative therapies include the potential for undetected disease progression. Patients with UTUC are more difficult to stage clinically than in bladder cancer. Endoscopic management can be performed ureteroscopically or percutaneously. Ideal indications include a unifocal tumor, small tumor size, and low-grade disease. A positive selective cytology suggests the presence of higher grade disease and potentially more advanced pathological T stage. Endoscopic technique is critical both for accurate diagnostic purposes and for safe performance of the procedure. The results of endoscopic therapy are highly dependent on tumor factors, with lowgrade tumors having much better results than high-grade tumors. The use of adjuvant topical therapy after complete endoscopic tumor control remains unclear. The strongest role for topical therapy for UTUC is for CIS, when it is used as primary therapy. The use of segmental or distal ureterectomy and partial nephrectomy for UTUC has narrow indications with the latter needing to be applied extremely selectively. Nephroureterectomy remains the gold standard treatment, but comes at the cost of significant loss of renal function. Single-dose treatment of the bladder after nephroureterectomy is considered a new standard of care, and could be considered an option by extension of this logic, to single-dose treatment after endoscopic therapy of the upper tracts.",
keywords = "Renal pelvis cancer, Surgical treatments, Survival, Ureteral cancer, Urothelial cancer",
author = "Husain, {Fatima Z.} and Mesut Remzi and Vitaly Margulis and Porten, {Sima P.} and Matin, {Surena F.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-1501-9_5",
language = "English (US)",
isbn = "9781493915019",
pages = "119--130",
booktitle = "Upper Tract Urothelial Carcinoma",
publisher = "Springer New York",

}

TY - CHAP

T1 - Conservative management of low-risk utuc

AU - Husain, Fatima Z.

AU - Remzi, Mesut

AU - Margulis, Vitaly

AU - Porten, Sima P.

AU - Matin, Surena F.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Conservative management of upper tract urothelial cancer (UTUC) treats tumor, prevents disease progression, lowers potential morbidity, and avoids unnecessary loss of renal function by avoiding nephroureterectomy. Limitations associated with conservative therapies include the potential for undetected disease progression. Patients with UTUC are more difficult to stage clinically than in bladder cancer. Endoscopic management can be performed ureteroscopically or percutaneously. Ideal indications include a unifocal tumor, small tumor size, and low-grade disease. A positive selective cytology suggests the presence of higher grade disease and potentially more advanced pathological T stage. Endoscopic technique is critical both for accurate diagnostic purposes and for safe performance of the procedure. The results of endoscopic therapy are highly dependent on tumor factors, with lowgrade tumors having much better results than high-grade tumors. The use of adjuvant topical therapy after complete endoscopic tumor control remains unclear. The strongest role for topical therapy for UTUC is for CIS, when it is used as primary therapy. The use of segmental or distal ureterectomy and partial nephrectomy for UTUC has narrow indications with the latter needing to be applied extremely selectively. Nephroureterectomy remains the gold standard treatment, but comes at the cost of significant loss of renal function. Single-dose treatment of the bladder after nephroureterectomy is considered a new standard of care, and could be considered an option by extension of this logic, to single-dose treatment after endoscopic therapy of the upper tracts.

AB - Conservative management of upper tract urothelial cancer (UTUC) treats tumor, prevents disease progression, lowers potential morbidity, and avoids unnecessary loss of renal function by avoiding nephroureterectomy. Limitations associated with conservative therapies include the potential for undetected disease progression. Patients with UTUC are more difficult to stage clinically than in bladder cancer. Endoscopic management can be performed ureteroscopically or percutaneously. Ideal indications include a unifocal tumor, small tumor size, and low-grade disease. A positive selective cytology suggests the presence of higher grade disease and potentially more advanced pathological T stage. Endoscopic technique is critical both for accurate diagnostic purposes and for safe performance of the procedure. The results of endoscopic therapy are highly dependent on tumor factors, with lowgrade tumors having much better results than high-grade tumors. The use of adjuvant topical therapy after complete endoscopic tumor control remains unclear. The strongest role for topical therapy for UTUC is for CIS, when it is used as primary therapy. The use of segmental or distal ureterectomy and partial nephrectomy for UTUC has narrow indications with the latter needing to be applied extremely selectively. Nephroureterectomy remains the gold standard treatment, but comes at the cost of significant loss of renal function. Single-dose treatment of the bladder after nephroureterectomy is considered a new standard of care, and could be considered an option by extension of this logic, to single-dose treatment after endoscopic therapy of the upper tracts.

KW - Renal pelvis cancer

KW - Surgical treatments

KW - Survival

KW - Ureteral cancer

KW - Urothelial cancer

UR - http://www.scopus.com/inward/record.url?scp=84944070784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944070784&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-1501-9_5

DO - 10.1007/978-1-4939-1501-9_5

M3 - Chapter

AN - SCOPUS:84944070784

SN - 9781493915019

SN - 9781493915002

SP - 119

EP - 130

BT - Upper Tract Urothelial Carcinoma

PB - Springer New York

ER -